CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle.Additionally, they control mRNA processing, transcription, and nerve cell differentiation. With molecular weights between 34 and 40 kDa, CDKs are relatively small proteins that only contain the kinase domain. In fact, when their CDK gene has been replaced with the homologous human gene, yeast cells can proliferate normally. A CDK by definition binds the control protein cyclin. Only the cyclin-CDK complex is an active kinase; CDK lacks much kinase activity on its own.
Around 20 Cyclin-dependent kinases (CDK1-20) have been identified as of yet. While CDK 7, 8, 9 and 11 are linked to transcription, CDK1, 4, and 5 are involved in the cell cycle.
The majority of CDK regulation occurs post-translationally, and CDK levels are essentially constant throughout the cell cycle. The majority of knowledge about CDK structure and function is based on CDKs from vertebrates (CDC2 and CDK2), S. pombe (CDC28), and S. cerevisiae (Cdc2). Cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and CDK inhibitory subunit (CKI) binding are the four main mechanisms of CDK regulation.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
![]() |
V55093 | CDK5-IN-1 | 2639540-19-3 | CDK5-IN-1 is a potent CDK5 inhibitor (antagonist) with less than 10 nM activity against CDK5. |
![]() |
V55101 | CDK7-IN-10 | 2588110-62-5 | CDK7-IN-10 is a CDK7 inhibitor (antagonist) with IC50 of less than 100 nM, found in patent WO2021016388A1, compound I-1. |
![]() |
V52275 | CDK7-IN-11 | 2414896-32-3 | CDK7-IN-11 is an orally bioactive CDK7 inhibitor. |
![]() |
V55073 | CDK7-IN-2 hydrochloride hydrate | 2326428-24-2 | CDK7-IN-2 HCl hydrate (Example 6) is a potent and specific CDK7 inhibitor. |
![]() |
V55092 | CDK7-IN-21 | 2766124-39-2 | CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor. |
![]() |
V55094 | CDK7-IN-22 | 2173190-60-6 | CDK7-IN-22 (compound 101) is a CDK7 inhibitor (antagonist) with anti-tumor activity. |
![]() |
V55089 | CDK7-IN-25 | 2009209-60-1 | CDK7-IN-25 (CY-16-1) is a CDK-7 inhibitor (IC50<1nM) and may be utilized in cancer-related research. |
![]() |
V78702 | CDK7-IN-26 | CDK7-IN-26 (compound 36) is an orally bioactive CDK7 inhibitor (IC50= 7.4 nM). | |
![]() |
V52274 | CDK7-IN-5 | 1817006-50-0 | CDK7-IN-5 is a CDK7 inhibitor (antagonist) with IC50 <100 nM. |
![]() |
V52273 | CDK7-IN-6 | 2378710-04-2 | CDK7-IN-6 is a potent and specific cyclin-dependent kinase (CDK7) inhibitor (IC50≤100 nM), found in patent WO2019197549 A1, compound 210. |
![]() |
V52272 | CDK7-IN-7 | 2640208-01-9 | CDK7-IN-7 is a potent CDK7 inhibitor (antagonist) with IC50 of <50 nM. |
![]() |
V77159 | CDK7/9 tide | CDK7/9 tide is a bioactive peptide substrate of CDK7 or CDK9. | |
![]() |
V52276 | CDK7/9-IN-1 | 2747919-19-1 | CDK7/9-IN-1 is a cyclin-dependent kinase 7/9 (CDK7/9) inhibitor. |
![]() |
V52271 | CDK8-IN-11 | 2839338-28-0 | CDK8-IN-11 is a potent and specific inhibitor of CDK8 with IC50 of 46 nM. |
![]() |
V52270 | CDK8-IN-12 | 2613307-67-6 | CDK8-IN-12 is an orally bioactive and potent CDK8 inhibitor (antagonist) with Ki of 14 nM. |
![]() |
V75992 | CDK8-IN-5 | 2855087-10-2 | CDK8-IN-5 is a potent inhibitor of CDK8 with IC50 of 72 nM. |
![]() |
V75978 | CDK8-IN-9 | 2850253-95-9 | CDK8-IN-9 (compound 22) is a potent type II CDK8 inhibitor (antagonist) with IC50 of 48.6 nM. |
![]() |
V55103 | CDK9 inhibitor HH1 | 204188-41-0 | CDK9 inhibitor HH1 is a potent and specific CDK9 inhibitor. |
![]() |
V79317 | CDK9-Cyclin T1 PPI-IN-1 | CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. | |
![]() |
V75993 | CDK9-IN-11 | 2748368-15-0 | CDK9-IN-11 is a potent CDK9 inhibitor. |